OTCM
CPMV
Market cap452kUSD
Oct 08, Last price
0.06USD
1D
0.00%
1Q
-90.22%
Jan 2017
-96.84%
Name
Mosaic Immunoengineering Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
55.45%
Rev. gr., 5y
%
Revenues
0
Net income
-688k
L-25.39%
CFO
-111k
L-53.81%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Mosaic ImmunoEngineering Inc. is an early-stage biotechnology firm dedicated to the advancement and commercialization of an immunomodulatory platform technology. This innovative platform aims to provide therapeutic solutions for cancer and infectious diseases in both human and animal health. The company's core product is MIE-101, a nanoparticle-based treatment sourced from the cowpea mosaic virus, which has demonstrated non-infectious characteristics in mice, dogs, and humans. Headquartered in Novato, California, the company commenced operations in 2020.
Key people
Paul Lytle
Chief Financial Officer, Executive Vice President, Corporate Secretary, Director · since 2020
Steven King
President, Chief Executive Officer, Director · since 2020
Robert Baffi
Independent Director · since 2021
Robert Garnick
Independent Director · since 2020
Legal address
c/o HARVARD BUSINESS SERVICES, INC., 16192 COASTAL HWY
LEWES, DE 19958
US
LEWES, DE 19958
US
Headquarters
2038 Corte Del Nogal
Carlsbad, CA 92011
US
Carlsbad, CA 92011
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2020‑05 | 2018‑05 | 2017‑05 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||